Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2022.10.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.
Int Arch Allergy Immunol
October 2024
Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent swelling due to a deficiency in a specific inhibitor, and lanadelumab has been the primary long-term treatment option in China since 2020.
- A study involving 6 patients showed that lanadelumab significantly reduced the frequency of HAE attacks by up to 98.5%, improved quality of life, and decreased lost workdays by nearly 99% during the initial treatment phases.
- The findings suggest that lanadelumab is both effective and safe for managing HAE in Chinese patients, maintaining its efficacy even during the COVID-19 pandemic without any severe adverse effects.
Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.
Ann Allergy Asthma Immunol
December 2024
Takeda Pharmaceuticals USA, Inc, Lexington, Massachusetts.
Background: Lanadelumab was well tolerated and effective in preventing hereditary angioedema (HAE) attacks in the phase 3, double-blind, placebo-controlled Hereditary angioEdema Long-term Prophylaxis (HELP) study and subsequent HELP open-label extension (OLE) study (NCT02741596).
Objective: To evaluate outcomes from HELP OLE for adolescent patients aged 12 to 17 years.
Methods: The HELP OLE study comprised patients who completed the HELP study (rollovers) and new eligible (lanadelumab-naive) patients.
The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
Front Immunol
May 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- Lanadelumab is a medicine used to help people with hereditary angioedema (HAE) and has been studied over 4 years for how well it works and if it's safe.
- Out of 34 patients treated with lanadelumab, most were still doing well after 4 years, with many reporting fewer attacks and feeling satisfied with their treatment.
- The study showed that lanadelumab is effective and safe in real life, and it suggests that patients may not need extra short-term treatments when using it.
Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series.
J Asthma Allergy
February 2024
Kanarek Allergy, Asthma & Immunology, Leawood, KS, USA.
Hereditary angioedema (HAE) is a rare genetic disorder characterized by potentially life-threatening episodes of swelling. Most HAE cases are caused by deficient (type I) or dysfunctional (type II) C1-esterase inhibitor (C1-INH) protein. However, some patients present with a subtype of HAE that is associated with normal plasma levels of functional C1-INH protein and complement component 4 (HAE-nC1INH).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!